The S1PR1 modulators approved for MS induce a more pronounced depletion of naïve and helper T cells in the peripheral blood compared to cytotoxic T cells, central memory T cells and peripheral effectors memory T cells, which should generally confer a favorable safety profile in respect to infections [17,18,36,37]. This evidence concerns the gene S1PR1 and myeloid sarcoma.